Applied Biosystems to Webcast Presentation at the Piper Jaffray Europe Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, will webcast its presentation at the Piper Jaffray Europe Conference in London on Wednesday, June 25, 2008. The live webcast is scheduled to begin at 9:40 a.m. GMT (4:40 a.m. EDT). Peter Dworkin, Vice President of Investor Relations and Corporate Communications for Applera Corporation, will provide an overview of Applied Biosystems’ business, including a brief summary of the proposed merger with Invitrogen Corporation, followed by a question and answer session.

Interested parties may access the live webcast and replay by visiting the Investors section of the Applied Biosystems website at http://ir.appliedbiosystems.com or the Investors & Media section of the Applera web site at www.applera.com. It is suggested that interested parties access the webcast 15 minutes before the start of the live webcast. The webcast replay will be archived on the Presentations page of the Investors section of each website.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. Applied Biosystems serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, such as testing required for food and pharmaceutical manufacturing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of approximately $2.1 billion during fiscal 2007. Celera is a diagnostics business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and optimize patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information unless required by law.

In connection with the proposed merger, Invitrogen will file with the SEC a Registration Statement on Form S-4 that will include a joint proxy statement of Applera and Invitrogen. Applera and Invitrogen will mail the joint proxy statement to their respective stockholders. Investors and security holders are urged to read the joint proxy statement when it becomes available because it will contain important information. You may obtain a free copy of the joint proxy statement (when it is available) and other related documents filed with the SEC by Applera and Invitrogen at the SEC’s website at www.sec.gov. The joint proxy statement (when it is available) and the other documents may also be obtained for free at Applera’s website at http://www.applera.com or at Invitrogen’s website at http://www.invitrogen.com.

Applera and Invitrogen and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of stockholders in connection with the merger will be set forth in the joint proxy statement when it is filed with the SEC. You can find information about Applera’s executive officers and directors in Applera’s definitive proxy statement filed with the SEC on September 6, 2007. You can find information about Invitrogen’s executive officers and directors in its definitive proxy statement filed with the SEC on March 5, 2008. You may obtain free copies of these documents from Applera or Invitrogen, as applicable, by using the contact information above.

Copyright© 2008. Applera Corporation. All Rights Reserved. AB (Design), Applied Biosystems, Applera, and Celera are registered